Global Artificial Lung Devices Pipeline Insight and Competitive Landscape Report 2021: Comprehensive Insights About 20+ Companies and 23+ Pipeline Devices – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Artificial Lung Devices – Pipeline Insight and Competitive Landscape, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Artificial Lung Devices-Pipeline Insight and Competitive Landscape, 2021,” report provides comprehensive insights about 20+ companies and 23+ pipeline devices in artificial lung devices pipeline landscape.

Globally, number of cases related to respiratory failure and cardiopulmonary collapse has grown rapidly. This has resulted in increasing demand for artificial lung that acts as an external support system providing oxygenation of blood and removal of carbon dioxide from the blood.

Researchers and scientists are also making persistent efforts in developing and improving artificial lung, with which it can be used at larger scale and with greater ease. Therefore, due to an increase in demand and more and more players investing in research and development activities, there is an extensive pipeline of artificial lung devices.

This latest report has all the emerging artificial lung devices along with competitive landscape to help better understand the market scenario.

Major Players in Artificial Lung Devices

There are approx. 20+ key companies which are developing the products for artificial lung devices.

Hemolung RAS: ALung Technologies, Inc

Hemolung RAS provides ultra-low-flow, veno-venous extracorporeal carbon dioxide removal (ECCO2R) using a single, 15.5 French dual lumen catheter inserted percutaneously in the femoral or jugular vein. Low-flow ECCO2R with the Hemolung RAS provides partial lung support independently of the lungs. The Hemolung RAS removes 25% – 50% of basal metabolic CO2 production at circuit blood flows of 350-550 mL/min. The Hemolung RAS is designed to minimize the complication risks associated with extracorporeal gas exchange therapy.

OXY-1: Breethe, Inc

Breethe’s system, called the OXY-1 System, is designed to remove carbon dioxide and add oxygen to a patient’s blood, much like a working human lung would. The tech eliminates the need for bulky oxygen tanks, and allows patients in need of ECMO therapy to move around more easily. Breethe has filed for clearance from the U.S. Food and Drug Administration for the OXY-1 System, but has not yet received it.

Xenolungs: Lung Biotechnology

Lung Biotechnology is actively progressing towards the research and development of xenolungs. They have been constantly trying to develop new technologies and products to alleviate access and improve outcomes in patients that are suffering from Pulmonary Arterial Hypertension (PAH) and other fatal diseases. Xenolungs are human-compatible lungs that are developed in genetically engineered pigs. The patients receiving lung transplants have an improved quality of life and higher chances of survival.

Key Players

• Lung Biotechnology
• Miromatrix
• Charles Stark Draper Laboratory Inc
• United Therapeutics Corporation
• XVIVO Perfusion
• Medtronic
• Getinge
• Xenios AG
• ALung Technologies Inc.
• MC3 Cardiopulmonary
• Abiomed

Artificial Lung Devices Overview

Artificial Lung Devices: Understanding

Artificial lung device is a prosthetic device works as an alternative to the biological lung. It provides oxygenation of blood and removal of carbon dioxide from the blood. Artificial lung devices are made of synthetic material that are connected to blood vessels through tubes and cannulas of silicone.

Who needs Artificial Lungs?

• Chronic obstructive pulmonary diseases (COPD) patients
• Idiopathic interstitial pneumonia (IIPs)
• Cystic Fibrosis (CF)
• Pulmonary Arterial Hypertension

Artificial Lungs Devices: Competitive Assessment

This segment of the artificial lung devices report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including latest news and press releases. The report also provides list of major players involved in the pipeline product development.

Product Type

Artificial lung devices for decades have been used in newborns and children with lung failure, pneumonia, meconium aspiration syndrome and other conditions. However, recently they have also been employed to be used in adults. Hence the segmentation of the report categories device products based on pediatric, adult, both.

Product Technology

Artificial lung devices can be used in two different ways – venovenous (VV) and venoarterial (VA), both the ways are covered in the report.

Approval

The assessment has been carried out on the basis of artificial lung device approval- FDA, CE Mark or both.

Stage

The competitive assessment of the pipeline devices has been given pertaining to their stage, whether they are in the clinical or the pre-clinical stage.

Artificial Lung Devices – Competitive Assessment

This segment of the report provides a brief competitive analysis of Artificial Lung Devices, to help understand the competition in the market. It gives a comparative understanding of the Artificial Lung Devices based on parameters such patient type.

Artificial Lung Devices: Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

• Brand Positioning of Leading companies
• Industry Collaborations

Artificial Lung Devices: Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of artificial lung devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

• In December 2020, Abiomed announced that it has treated two patients in the world with the AbiomedBreethe OXY-1 System, a compact cardiopulmonary bypass system. It is an advanced ECMO technology along with pumps and oxygenator that removes carbon dioxide from the blood for patients whose lungs can no longer provide sufficient organ (ABIOMED, Inc., 2020).

Artificial Lung Devices Report Insights

• Artificial Lung Devices – Pipeline Analysis
• Artificial Lung Devices – Unmet Need
• Artificial Lung Devices – Market Dynamics
• Artificial Lung Devices – Future Perspectives and Conclusion
• Artificial Lung Devices- Analyst Views

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xxk8x9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900